Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Kymriah to Face 4% Price Cut in 1st CEA-Based Price Tweak, Yescarta Too
Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) will get a price reduction of around 4% in the first price adjustment under the Japanese cost-effectiveness assessment (CEA) scheme, which will also affect Daiichi Sankyo’s yet-to-be-listed Yescarta (axicabtagene ciloleucel), people familiar with the…
To read the full story
Related Article
- Japan Officially Announces CEA-Based Prices for Kymriah/Trelegy, Effective July 1
April 21, 2021
- Yescarta to Join NHI Price List on April 21, Gets CEA-Tweak from Get-Go
April 14, 2021
- Kymriah to Get 4.3% Reduction, Trelegy 0.5% Cut in 1st CEA-Based Price Tweak
April 14, 2021
- Japan Publishes Cost-Effectiveness Analysis Reports for Kymriah, Trelegy
April 1, 2021
- Chuikyo OKs Appraisal Results for Kymriah, Trelegy; Downward Price Tweaks Expected
March 25, 2021
- Appraisal Results for Kymriah, Trelegy Up for Chuikyo Review on March 24; Price Cuts Likely
March 23, 2021
- Chuikyo OKs Flow of CEA-Based Re-Pricing, New Price Effective 3 Months after Announcements
February 12, 2021
REGULATORY
- Pharma Continues Reform Push at 2nd Public-Private Subgroup Meeting
October 13, 2026
- AbbVie’s TrenibotE Up for Review on Oct. 26, Aquipta on Agenda Too
October 13, 2026
- Japan Panel to Review Full Approval of Nipro’s Stemirac on October 15
October 13, 2026
- Japan Finalizes Medical Data Sharing Blueprint, Eyes 2027 Bill
October 13, 2026
- AlliedCel Takes Over Sakigake Designation for Junten Bio’s T-Cell Therapy
October 13, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…